Quarterly ResultMay 7, 2026, 09:13 AM
Praxis Q1 Net Loss $(92.6)M; Cash & Securities $1.4B
AI Summary
Praxis Precision Medicines reported a net loss of $(92.6) million for the first quarter of 2026, an increase from $(69.3) million in Q1 2025. Operating expenses rose significantly, driven by increased research and development and general and administrative costs. However, the company substantially strengthened its financial position through a follow-on public offering, boosting cash, cash equivalents, and marketable securities to $1.4 billion, which is expected to fund operations for at least one year.
Key Highlights
- Net loss for Q1 2026 was $(92.6) million, compared to $(69.3) million in Q1 2025.
- Total operating expenses increased to $105.9 million in Q1 2026 from $74.7 million in Q1 2025.
- Research and development expenses rose to $78.0 million in Q1 2026 from $60.8 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $1.4 billion as of March 31, 2026.
- Net cash provided by financing activities was $609.4 million in Q1 2026, primarily from a public offering.
- Net loss per share was $(3.20) for Q1 2026, compared to $(3.29) for Q1 2025.
- Accumulated deficit reached $(1.23) billion as of March 31, 2026.